Crinetics Pharmaceuticals, Inc.
- Jurisdiction
United States - LEI
549300Q1CNFXK5P31D28 - ISIN
US22663K1079 (CRNX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
5
/ 7
Profile
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Read full profile
Fundamentals
- Net revenue
€1.19M - Gross margin
31.1% - EBIT
-€360.85M - EBIT margin
-30,392.2% - Net income
-€315.45M - Net margin
-26,568.5%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Pizzuti Dana | Chief Med and Dev Officer |
|
|
|
|
| Pizzuti Dana | Chief Med and Dev Officer |
|
|
|
|
| Pizzuti Dana | Chief Med and Dev Officer |
|
|
|
|
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| Gilbert Cisneros | May 6, 2025 | $1.00K–$15.00K |
| Josh Gottheimer | April 10, 2025 | $1.00K–$15.00K |
| Gilbert Cisneros | February 11, 2025 | $1.00K–$15.00K |
| Josh Gottheimer | October 3, 2024 | $1.00K–$15.00K |
Earnings Calls
Earnings Calls
Latest earnings call: May 9, 2024 (Q1 2024)